Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Burger

Showing results (21-30 of 337) with videos related to

Pageof 34
Sort By:
Therapeutic Drug Monitoring|July 2, 2004
Therapeutic drug monitoring in children with HIV/AIDSPieter L A Fraaij, Natella Rakhmanina, David M Burger, et al.
The Pediatric Infectious Disease Journal|January 12, 2022
Raltegravir-based Postnatal HIV Prophylaxis Therapy in a Neonate After in Utero Dolutegravir ExposureTom G Jacobs, Koen J van Aerde, Angela Colbers, et al.
Alimentary Pharmacology & Therapeutics|December 17, 2019
Review article: clinical pharmacology of current and investigational hepatitis B virus therapiesElise J Smolders, David M Burger, Jordan J Feld, et al.
Therapeutic Drug Monitoring|April 22, 2006
False-positive results in urine drug screening in healthy volunteers participating in phase 1 studies with efavirenz and rifampinCharles J L la Porte, Jacqueline A H Droste, David M Burger
British Journal of Clinical Pharmacology|July 18, 2006
The effect of the CYP2C19*2 heterozygote genotype on the pharmacokinetics of nelfinavirDavid M Burger, H Reinier Schwietert, E P H Colbers, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 2, 2005
The pharmacology of antiretroviral nucleoside and nucleotide reverse transcriptase inhibitors: implications for once-daily dosingDavid J Back, David M Burger, Charles W Flexner, et al.
Clinical Pharmacokinetics|July 23, 2020
Drug-Drug Interactions with Antiretroviral Drugs in Pregnant Women Living with HIV: Are They Different from Non-Pregnant Individuals?Vera E Bukkems, Angela Colbers, Catia Marzolini, et al.
Expert Opinion on Drug Metabolism & Toxicology|June 1, 2014
The role of formulation on the pharmacokinetics of antiretroviral drugsDiane E T Bastiaans, Tim R Cressey, Herman Vromans, et al.
Clinical Pharmacokinetics|September 28, 2018
Cardiovascular Risk Management and Hepatitis C: Combining DrugsElise J Smolders, Peter J G Ter Horst, Sharon Wolters, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 13, 2005
Assessment of drug-drug interactions between tenofovir disoproxil fumarate and the nonnucleoside reverse transcriptase inhibitors nevirapine and efavirenz in HIV-infected patientsJacqueline A H Droste, Brian P Kearney, Yechiel A Hekster, et al.
Pageof 34

Showing results (21-30 of 337) with videos related to

Sort By:
Pageof 34
Therapeutic Drug Monitoring|July 2, 2004
Therapeutic drug monitoring in children with HIV/AIDSPieter L A Fraaij, Natella Rakhmanina, David M Burger, et al.
The Pediatric Infectious Disease Journal|January 12, 2022
Raltegravir-based Postnatal HIV Prophylaxis Therapy in a Neonate After in Utero Dolutegravir ExposureTom G Jacobs, Koen J van Aerde, Angela Colbers, et al.
Alimentary Pharmacology & Therapeutics|December 17, 2019
Review article: clinical pharmacology of current and investigational hepatitis B virus therapiesElise J Smolders, David M Burger, Jordan J Feld, et al.
Therapeutic Drug Monitoring|April 22, 2006
False-positive results in urine drug screening in healthy volunteers participating in phase 1 studies with efavirenz and rifampinCharles J L la Porte, Jacqueline A H Droste, David M Burger
British Journal of Clinical Pharmacology|July 18, 2006
The effect of the CYP2C19*2 heterozygote genotype on the pharmacokinetics of nelfinavirDavid M Burger, H Reinier Schwietert, E P H Colbers, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 2, 2005
The pharmacology of antiretroviral nucleoside and nucleotide reverse transcriptase inhibitors: implications for once-daily dosingDavid J Back, David M Burger, Charles W Flexner, et al.
Clinical Pharmacokinetics|July 23, 2020
Drug-Drug Interactions with Antiretroviral Drugs in Pregnant Women Living with HIV: Are They Different from Non-Pregnant Individuals?Vera E Bukkems, Angela Colbers, Catia Marzolini, et al.
Expert Opinion on Drug Metabolism & Toxicology|June 1, 2014
The role of formulation on the pharmacokinetics of antiretroviral drugsDiane E T Bastiaans, Tim R Cressey, Herman Vromans, et al.
Clinical Pharmacokinetics|September 28, 2018
Cardiovascular Risk Management and Hepatitis C: Combining DrugsElise J Smolders, Peter J G Ter Horst, Sharon Wolters, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 13, 2005
Assessment of drug-drug interactions between tenofovir disoproxil fumarate and the nonnucleoside reverse transcriptase inhibitors nevirapine and efavirenz in HIV-infected patientsJacqueline A H Droste, Brian P Kearney, Yechiel A Hekster, et al.
Pageof 34